Digestive Disease Interventions 2020; 04(04): 358-364
DOI: 10.1055/s-0040-1721453
Review Article

Combination Therapies with Ablation: Immunoablation

1  Division of Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, Maryland
,
2  Department of Interventional Radiology, Guy's & St. Thomas Hospital, London, United Kingdom
,
1  Division of Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, Maryland
› Author Affiliations
Funding This study was not supported by any funding.

Abstract

Percutaneous ablation has been increasingly utilized as an alternative or adjunct to surgical resection of solid tumors. However, high rates of local recurrence and disease progression both with resection and ablation, particularly in patients with primary and metastatic liver malignancies, have limited further extension of overall survival. Systemic oncology treatment has progressed beyond traditional chemotherapeutic agents to immunotherapeutic agents that exert their effect by enhancing the body's immune response against cancer cells. The induction of necrotic cell death and the release of a large number of tumor antigens as a result of ablation have stimulated interest in combination therapy as a potential method of improving response to immunotherapy. This review focuses on the current scientific evidence for combination therapy of immuno-oncologic agents and locoregional ablation techniques.



Publication History

Received: 09 July 2020

Accepted: 24 August 2020

Publication Date:
19 November 2020 (online)

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA